Cargando…

Progress of immunotherapy in the treatment of malignant melanoma.

Detalles Bibliográficos
Autor principal:	Ariyan, S.
Formato:	Texto
Lenguaje:	English
Publicado:	Yale Journal of Biology and Medicine 1975
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2595262/ https://www.ncbi.nlm.nih.gov/pubmed/1108459

Ejemplares similares

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

Malignant Melanoma in Older Adults: Different Patient or Different Disease?
por: Sasson, Daniel C, et al.
Publicado: (2023)

Eruptive melanocytic nevi heralding the diagnosis of metastatic malignant melanoma: A case report
por: Kibbi, Nour, et al.
Publicado: (2015)

Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies
por: Dillon, Alexander B., et al.
Publicado: (2015)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Testosterone deficiency in men receiving immunotherapy for malignant melanoma
por: Peters, Madeline, et al.
Publicado: (2021)

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
por: Currie, G. A., et al.
Publicado: (1975)

BAP31, a promising target for the immunotherapy of malignant melanomas
por: Yu, Shaojuan, et al.
Publicado: (2015)

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2019)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
por: Pavlick, Anna C, et al.
Publicado: (2023)

Bilateral anterior uveitis after immunotherapy for malignant melanoma
por: Chang, Chia-Jui, et al.
Publicado: (2018)

Immunotherapy against esophageal primary amelanotic malignant melanoma relapse
por: Tsukamoto, Ryoichi, et al.
Publicado: (2021)

Immunotherapy-Induced Auto-Splenectomy in a Patient of Malignant Melanoma
por: Ehsanullah, Syed, et al.
Publicado: (2022)

The use of immunotherapy in the treatment of melanoma
por: Achkar, Tala, et al.
Publicado: (2017)

Bispecific Antibodies Progression in Malignant Melanoma
por: Tang, Juan, et al.
Publicado: (2022)

Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
por: Embleton, M. J., et al.
Publicado: (1978)

Immunotherapy of melanoma
por: Haanen, John B.A.G.
Publicado: (2013)

Role of miRNAs in the progression of malignant melanoma
por: Mueller, D W, et al.
Publicado: (2009)

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
por: Lambing, Silke, et al.
Publicado: (2023)

Melanoma immunotherapy
por: Garg, Abhishek D., et al.
Publicado: (2015)

Immunotherapy of melanoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

Development of novel parameter for monitoring of malignant melanoma progression
por: Špaková, Ivana, et al.
Publicado: (2020)

Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma
por: Le Rhun, Emilie, et al.
Publicado: (2020)

Current status and progress in immunotherapy for malignant pleural mesothelioma
por: Sun, Boyang, et al.
Publicado: (2022)

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2021)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Treatment of In-Transit Melanoma With Intralesional Bacillus Calmette-Guérin (BCG) and Topical Imiquimod 5% Cream: A Report of 3 Cases
por: Kibbi, Nour, et al.
Publicado: (2015)

Novel anti-melanoma treatment: focus on immunotherapy
por: Hao, Meng-Ze, et al.
Publicado: (2014)

Immunotherapies for the Treatment of Uveal Melanoma—History and Future
por: Schank, Timo E., et al.
Publicado: (2019)

Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
por: Kim, Dae Suk, et al.
Publicado: (2011)

Cell Proliferation in Cutaneous Malignant Melanoma: Relationship with Neoplastic Progression
por: Piérard, G. E.
Publicado: (2012)

Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
por: Xu, Zhengli, et al.
Publicado: (2021)

Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy
por: Genova, Pietro, et al.
Publicado: (2017)

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report
por: Yasuda, Koji, et al.
Publicado: (2017)

Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A Meta-Analysis
por: Surov, Alexey, et al.
Publicado: (2022)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

SIRT1 regulates Mxd1 during malignant melanoma progression
por: Meliso, Fabiana M., et al.
Publicado: (2017)

Abstract 139: Prognostic Factors In Determining The Recurrence Of Desmoplastic Melanoma
por: Persing, Sarah, et al.
Publicado: (2019)

Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab: A case report
por: Ma, Qin, et al.
Publicado: (2021)

Malignant melanoma
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_s1fgvhov40duepvl22vrq3125a